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The neurovascular unit is an emerging concept that emphasizes
homeostatic interactions between endothelium and cerebral paren-
chyma. Here, we show that cerebral endothelium are not just inert
tubes for delivering blood, but they also secrete trophic factors that
can be directly neuroprotective. Conditioned media from cerebral
endothelial cells broadly protects neurons against oxygen-glucose
deprivation, oxidative damage, endoplasmic reticulum stress, hyp-
oxia, and amyloid neurotoxicity. This phenomenon is largely medi-
ated by endothelial-produced brain-derived neurotrophic factor
(BDNF) because filtering endothelial-conditioned media with TrkB-Fc
eliminates the neuroprotective effect. Endothelial production of
BDNF is sustained by -1 integrin and integrin-linked kinase (ILK)
signaling. Noncytotoxic levels of oxidative stress disrupts ILK signal-
ing and reduces endothelial levels of neuroprotective BDNF. These
data suggest that cerebral endothelium provides a critical source of
homeostatic support for neurons. Targeting these signals of matrix
and trophic coupling between endothelium and neurons may provide
new therapeutic opportunities for stroke and other CNS disorders.
brain injury  neurodegeneration  neurovascular  stroke
Over the past decade, intricate molecular mechanisms ofneuronal cell death have been dissected in great detail
(1–6). However, despite these impressive advances, a clinically
proven neuroprotective therapy against CNS injury and neuro-
degeneration does not exist. This problem is especially obvious
in stroke, where a staggering number of clinical trials for
neuroprotection have all failed. An emerging consensus in the
field now suggests that a singular focus on neurons alone may not
suffice. All cell types must be considered within the entire
‘‘neurovascular unit,’’ comprising interactions between neurons,
glia, and the cerebral endothelium (7). Thus protecting neurons
alone may not work, and all cells and perhaps cell–cell interac-
tions within the brain must be rescued.
The concept of the neurovascular unit especially emphasizes the
central importance of homeostatic interactions between endothe-
lium and neuronal parenchyma (8–13). Coupling within the neu-
rovascular unit can be manifested in many ways. At a tissue level,
hemodynamic coupling mediates the cerebral blood flow response
to neuronal activation (14). Without this coupling, the brain cannot
function even if neurons are alive. At a cellular level, interactions
between endothelium and neuroblasts promote neurogenesis and
brain recovery (15, 16). Stimulation of angiogenesis amplifies
neurogenesis, whereas blockade of vascular signals suppresses
neurogenesis after stroke (17, 18). Is it possible that additional
facets of endothelial-neuronal signaling are essential for supporting
neuronal survival? In this study, we explore the hypothesis that
matrix-trophic coupling between cerebral endothelium and neu-
rons is fundamentally neuroprotective.
Results
Cerebral Endothelial Cells Are Neuroprotective. Neurons are known
to be especially vulnerable to hypoxia and oxidative stress (1).
Exposure to 8 h of hypoxia followed by 16 h of reoxygenation
killed primary cortical neurons in cell culture (Fig. 1A). How-
ever, when neurons were cocultured in a transwell system
together with either primary mouse cerebral endothelial cells or
a human brain endothelial cell line, neurotoxicity was signifi-
cantly reduced (Fig. 1 A). Because there is no direct cell–cell
contact in our transwell culture system, these data suggest that
cerebral endothelial cells may secrete potent neuroprotective
factors.
To further extend these coculture observations, we turned to
an experimental paradigm previously established to dissect
coupling between endothelium and neurogenesis (19). Cerebral
endothelial cells were grown separately, and endothelial-
conditioned media (E-CM) were then added to primary neuro-
nal cultures subjected to hypoxic injury. Control neurons were
treated with ‘‘conditioned media’’ derived from empty wells
without endothelial cells. In control neurons, hypoxia led to the
expected degree of neurotoxicity. But in neurons that were
treated with conditioned media from cerebral endothelial cells,
cell death was significantly ameliorated (Fig. 1B). The endothe-
lial specificity of these findings was supported by an additional
set of cells where neuroprotection was not observed when the
injured neurons were treated with neuron-conditioned media
(N-CM), i.e., media collected from uninjured matching neuronal
cultures (Fig. 1B).
Because multiple injury mechanisms are triggered after
stroke, brain injury, and neurodegeneration, we tested our
hypothesis in several different neuronal injury paradigms. The
protective effect of E-CM was efficacious against a wide range
of insults. These included exposure to amyloid- (Fig. 1C),
oxygen-glucose deprivation (OGD) (Fig. 1D), direct oxidative
damage with H2O2 (Fig. 1D), and endoplasmic reticulum (ER)
stress (Fig. 1D). Once again, control injury-only neurons were
treated with conditioned media derived from empty wells with-
out endothelial cells. Taken together, these results indicate that
some soluble factor released by cerebral endothelium comprises
a potent protective mediator against multiple forms of neuro-
toxicity.
Cerebral Endothelial Cells Are Neuroprotective by Secreting Brain-
Derived Neurotrophic Factor (BDNF). What are cerebral endothelial
cells making that is neuroprotective? Cerebral endothelial cells
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are known to be an important source of BDNF (15, 20–22). In
our cell culture systems, cerebral endothelial cells appear to
produce BDNF at a rate of 50 pg per 106 cells over 24 h. In
contrast, BDNF production by cortical neurons was much lower
at a rate of 1 pg per 106 cells over 24 h. Therefore, we tested
the initial hypothesis that BDNF was a soluble factor responsible
for neuroprotection in our conditioned-media transfer experi-
ments. The soluble antagonist TrkB-Fc were used to prevent
BDNF from binding onto TrkB, the primary BDNF receptor in
neurons. Our results showed that TrkB-Fc eliminated the pro-
tective effects of E-CM against hypoxia-induced neurotoxicity
(Fig. 2A). Because directly adding TrkB-Fc may affect multiple
pathways in the recipient neuronal cultures, we sought to further
test this hypothesis with another approach. E-CM were filtered
with TrkB-Fc to remove BDNF, and then the filtered media were
added to neurons before they were subjected to hypoxic injury.
Western blots and ELISAs suggested that we effectively removed
99% of all detectable BDNF with this filtering method. When
compared against unfiltered media or controls filtered with
nonspecific IgG, the neuroprotective effects of TrkB-Fc-filtered
E-CM was significantly reduced (Fig. 2 B and C). To further
establish BDNF as the primary neuroprotective mediator, we
next performed a rescue experiment. When exogenous BDNF
was added back to the TrkB-Fc-filtered endothelial media,
neuroprotection against hypoxia was mostly restored (Fig. 2C).
Finally, we decided to confirm our neurotoxicity data by mea-
suring cell viability instead. We repeated the basic experiments
by measuring mitochondrial tetrazolium (MTT)-converting ac-
tivity as a standard indicator of neuronal cell viability. Once
again, endothelial-conditoned media was protective against hyp-
oxia, whereas removing BDNF by filtering the media with
TrkB-Fc essentially eliminated the neuroprotection (Fig. 2D).
Nonlethal Levels of Oxidative Stress Suppress Endothelial BDNF Pro-
duction. Thus far, our data suggest that BDNF might be a trophic
link between cerebral endothelium and neuronal survival. If so,
then it is conceivable that endothelial stress and injury could disrupt
this potentially important source of trophic neurovascular coupling.
To assess this hypothesis, we exposed cerebral endothelial cells to
amyloid-, which is known to damage brain vasculature (13, 23, 24).
As expected, increasing concentrations of amyloid- triggered
endothelial cell death. But even at noncytotoxic levels, amyloid-
still appeared to significantly reduce secreted BDNF levels (Fig.
3A). Is oxidative stress an important part of this phenomenon? A
pharmacologic approach was used to assess this possibility. Treat-
ment with the potent and relatively specific antioxidant U83836E
Fig. 2. Role of BDNF in E-CM for neuroprotection. (A) E-CM protects against
24 h of hypoxia in primary rat neurons. TrkB-Fc (2 g/ml) eliminates the
neuroprotective properties of E-CM. Treatment with nonspecific IgG (2 g/ml)
has no effects. Neurotoxicity is quantified with the standard LDH release assay.
(B) Representative images show primary neurons damaged by 24 h of hypoxia,
rescue by E-CM, and blockade of E-CM neuroprotection with TrkB-Fc (2 g/ml)
filtering. (Magnification: 2020) (C) E-CM neuroprotection against 24 h of
hypoxia (H24) is lost when E-CM is filtered with TrkB-Fc (2 g/ml) to remove
BDNF. Addition of exogenous BDNF (10 ng/ml) restores the neuroprotective
effect. Positive controls directly treated with exogenous BDNF are also pro-
tected. Neurotoxicity is quantified as LDH release from dying cells. (D) The
neuroprotective capacity of conditioned media from cerebral endothelial cells
is further confirmed with a cell viability assay. Hypoxia for 24 h reduced
neuronal viability (MTT conversion). Treatment with E-CM provided signifi-
cant neuroprotection. Filtering with TrkB-Fc to remove BDNF eliminated the
neuroprotective effects of E-CM. *, P  0.05 between hypoxic neurons alone
versus neuron-endothelial cocultures or E-CM-treated neurons; #, P  0.05
between E-CM versus TrkB-Fc-filtered E-CM conditions.
Fig. 1. Cerebral endothelial cells provide neuroprotection via secretion of
BDNF. (A) Coculture of rat cortical neurons with either primary mouse cerebral
endothelial cells or a human brain endothelial cell line reduces neurotoxicity
after 8 h of hypoxia and 16 h of reoxygenation. (B) Neuroprotection is also
obtained by using transfer of E-CM. No protection is observed with N-CM. (C)
Neuronal death after 24 h of exposure to 25 g/ml (6 M) of amyloid- 1–40,
is significantly reduced by treatment with E-CM. Amyloid- 1–40 was chosen
because this isoform tends to be more commonly associated with brain
vasculature than the parenchymal (1–42) forms. (D) In SHSY5Y human neu-
roblastoma cells, E-CM protects against OGD, 24 h of exposure to 100 M of
H2O2, and 24 h of ER stress using 100 nM thapsigargin. Neurotoxicity was
quantified with a standard measurement of LDH release from dying cells. Note
that in all control ‘‘injury-only’’ conditions, neurons were treated with equiv-
alent amounts of media derived from empty wells without endothelial cells.











































ameliorated the amyloid-induced reduction in BDNF suppression
(Fig. 3B), thus indirectly supporting this idea. To further confirm
these findings, endothelial cells were exposed to sodium nitroprus-
side (SNP) as a nitric oxide donor and well accepted trigger of
downstream nitrosative and oxidative stress. At levels of SNP that
were not directly cytotoxic, endothelial BDNF production was
clearly reduced (Fig. 3C). Taken together, these data suggest that
oxidative stress can suppress trophic factor production in cerebral
endothelium without outright cell death.
-1 Integrins and Integrin-Linked Kinase (ILK) Mediate Endothelial
BDNF Production. The central idea of trophic coupling between
cerebral endothelium and neuronal survival is important be-
cause after stroke, brain injury, and perhaps even in neurode-
generarive diseases, neurovascular coupling may be perturbed in
many ways (8–13). Recent data suggest that the intercellular
matrix mediates neurovascular signaling so that disruption of
cell-matrix homeostasis underlies brain cell dysfunction and
death (10). If BDNF is important for neurovascular coupling, we
next asked how it is regulated in cerebral endothelium. Is it
possible that matrix integrity sustains endothelial BDNF? It is
known that amyloid and oxidative stress suppresses matrix
integrin signaling (25, 26), so we hypothesized that integrins may
mediate endothelial trophic responses in our model system. We
initially assessed -1 integrins because these are prominently
expressed in endothelial cells (26). Incubation of cerebral en-
dothelial cultures with increasing concentrations of the -1
blocking antibody mAb13 down-regulated BDNF production in
a manner similar to oxidative stress (Fig. 4A). In contrast,
stimulation with the potent -1-activating antibody 8A2 up-
regulated BDNF production (Fig. 4B). To further support the
specificity of these findings, -1-activating and -blocking anti-
bodies were added together. Our results showed that mAb13
reduced the elevation in BDNF induced by 8A2 (Fig. 4C). These
data suggest that at least in our cell model system -1 integrins
comprise critical matrix regulators of BDNF homeostasis in
cerebral endothelium. Therefore, when neurovascular matrix is
degraded in CNS disease and injury (10, 26–28), endothelium
might no longer be able to produce neuroprotective BDNF.
Once endothelial matrix integrins are disrupted, how does the
loss of outside-in signaling lead to a down-regulation of BDNF?
-1 integrin signaling typically occurs via ILK activity (29), so
ILK was next assessed as a candidate signal in our experimental
paradigms. We used both pharmacologic and genetic ap-
proaches. First, oxidative stress induced by amyloid- decreased
levels of endothelial phospho-Akt, a downstream target of ILK
(Fig. 5A). In contrast, -1 integrin stimulation with 8A2 in-
Fig. 3. Suppression of endothelial BDNF by nonlethal oxidative stress. (A)
Exposure of cerebral endothelial cells for 24 h to 5–40 M amyloid- 1–40 did
not induce detectable cell death in our model system. But BDNF levels in the
E-CM are significantly suppressed by 10–40 M amyloid- 1–40. Cytotoxicity
is assessed with LDH release *, P  0.05 versus undamaged endothelial cells. (B)
Cotreatment of endothelial cells with 5–10 M antioxidant U83836E prevents
the amyloid-induced suppression of BDNF production. *, P  0.05 versus
undamaged endothelial cells. #, P  0.05 versus cells damaged with 10 M
amyloid-. (C) Treatment of cerebral endothelial cells with 50–100 M of the
NO donor SNP did not induce any detectable cell death, but significantly
reduces BDNF production. Cytotoxicity is quantified as LDH release from dying
endothelial cells. *, P  0.05 versus undamaged cells.
Fig. 4. -1 integrin as a matrix input for BDNF production by cerebral
endothelial cells. (A) Exposure of cerebral endothelial cells for 24 h to the -1
integrin blocking antibody mAb13 (0.05–1 g/ml) reduces secreted BDNF. *,
P  0.05 versus baseline levels. (B) Conversely, treatment with the -1 integrin
stimulating antibody 8A2 (1:500 to 1:25) increases BDNF production from
cerebral endothelial cells. Controls treated with nonspecific IgG shows no
response. (C) -1 blockade with 1 g/ml mAb13 prevents BDNF production
stimulated with 8A2 (1:100). IgG (1 g/ml) has no effect. *, P  0.05 versus
untreated cells. #, P  0.05 between 8A2 alone versus 8A2 plus mAb13
conditions. No overt cytotoxicity occurred with these various integrin anti-
body treatments.




































creased the phosphorylation of two well established ILK targets,
i.e., GSK3- and Akt. Because both GSK3- and Akt can, of
course, be phosphorylated by many kinases besides ILK, we also
performed an inhibitor experiment. The potent and relatively
specific ILK inhibitor KP-392 significantly blocked -1 integrin-
stimulated changes in phospho-Akt and phospho-GSK3-, con-
sistent with the idea that ILK signaling mediates these responses
(Fig. 5B). Correspondingly, 8A2-mediated elevations in endo-
thelial BDNF was suppressed by KP-392 as well (Fig. 5C). Next,
we used an siRNA approach. Cerebral endothelial cells were
transfected with siRNA targeted against ILK (ILK-A) or a
scrambled siRNA nonsilencing control (NC). ILK expression
was effectively down-regulated by ILK-A (Fig. 5D), and corre-
spondingly, BDNF levels in E-CM were also significantly re-
duced by 60% (Fig. 5D). Finally, if ILK truly underlies BDNF
production in cerebral endothelial cells, then we have to predict
that down-regulation of ILK signals should negate the neuro-
protective effects of E-CM. When conditioned media from
ILK-suppressed cerebral endothelium were then added to neu-
ronal cultures, protection against hypoxia was lost (Fig. 5E).
Taken together, these data suggest that ILK-mediated BDNF
production may mediate neuroprotective matrix-trophic cou-
pling between the vascular and parenchymal compartments in
brain.
Discussion
Our data demonstrate that cerebral endothelial cells are an
important source of BDNF that protects neurons from a wide
range of neuronal insults including hypoxia, OGD, oxidative
damage, ER stress, and amyloid toxicity. Endothelial BDNF is
regulated by -1 integrins that act through ILK. Levels of
oxidative stress that do not overtly induce cell death can down-
regulate endothelial ILK signaling and BDNF production, thus
potentially disrupting this critical source of neurotrophic sup-
port. Our present findings are significant because they imply that
cerebral endothelial cells do not just comprise inert tubes for
delivering blood flow, oxygen, and glucose into brain. Instead,
they might additionally serve as active sources of neurotrophic
mediators that help defend neuronal tissue against injury and
disease. Our TrkB filtering data suggest that BDNF likely plays
a dominant role. But the ‘‘rescue’’ experiment where we added
back exogenous BDNF after TrkB filtering did not fully prevent
neuronal death. This phenomenon implies that other growth
factors are involved. In our cerebral endothelial cell system, a
gene array detected a wide range of trophic factors, and oxidative
stress was able to broadly down-regulate many of these mediators
[supporting information (SI) Fig. S1, Fig. S2, and Table S1].
Future studies are warranted to examine the network response
of these other mediators in the trophic coupling between brain
endothelium and neurons. In vivo, these hypotheses would also
be testable by using either inducible brain-endothelial-specific
growth factor knockouts or antioxidants that can target brain
endothelium without affecting other cell types.
Our study is consistent with the emerging notion that pertur-
bations in the health of cerebral endothelium may mediate
progressive neuronal dysfunction. Long-term follow-up of so-
called silent strokes reveal that significant cognitive impairment
occurs over time (30). In fact, endothelial mediators and risk
factors may significantly contribute not only to deterioration
after stroke, but also to progressive vascular dementia (31, 32).
In Alzheimer’s disease, amyloid may trigger oxidative stress in
brain endothelium via RAGE receptors, and perturbations in
amyloid transport mechanisms further add to a positive feedback
loop that damages both neuronal and vascular compartments
even more (33). From a clinical perspective, sick cerebrovascu-
lature may eventually lead to sick neurons, even in the absence
of primary cell death. Our findings suggest that oxidatively
challenged endothelium may lose the ability to provide trophic
support to neurons, even in the absence of vascular cell death or
blood flow compromise. Thus trying to save neurons alone
without preserving this critical endothelial source of BDNF may
not be enough for true neuroprotection. The need to protect the
vasculature in stroke and neurodegeneration is beginning to be
recognized (34, 35). Our data here provide additional evidence
as to why this is important.
Beyond neuroprotection, our present findings can also be
interpreted more broadly. To date, two forms of coupling and
signaling are known to exist between neurons and cerebral
endothelium. Fast hemodynamic coupling at the millisecond
time scale allows blood vessels to dilate and respond to neuronal
activity and metabolic demand (14). On a slower time scale,
neurovascular interactions within the stem cell niche contribute
to ongoing neurogenesis in adult brain (15–17, 19). Our data
here suggest another critical level of neurovascular coupling that
may be mediated via matrix and trophic interactions. However,
several caveats will require further study. Our initial data
support a major role for -1 integrins, but the dynamic role of
other integrins and cell types will need to be carefully dissected.
Furthermore, how quickly and how far these intercellular signals
propagate remains unknown. Our results implicate oxidative
stress as a potential upstream trigger that perturbs this form of
trophic coupling. But other pathways may also be triggered
simultaneously. For example, matrix metalloproteinases are
dysregulated in stroke, trauma, and neurodegeneration (10, 36,
37). Aberrant metalloproteinase activity can degrade neurovas-
cular matrix and interrupt the baseline secretion of endothelial
Fig. 5. ILK as a mediator to couple neuroprotective matrix-trophic signaling
in cerebral endothelial cells. (A) Oxidative stress with amyloid- 1–40 de-
creases phospho-Akt, a downstream target of ILK. (B) Activation of -1 inte-
grins with 8A2 increased phospho-GSK3- and phospho-Akt, both targets of
ILK. These integrin signaling responses are blocked by the ILK inhibitor KP-392
(100 M). (C) Stimulation of -1 integrins with 8A2 increases BDNF production
by cerebral endothelial cells, and the ILK inhibitor KP-392 blocks this response.
*, P  0.05 versus baseline; #, P  0.05 between 8A2-treated cells and 8A2 plus
KP-392-treated cells. (D) siRNA reduces ILK expression in cerebral endothelial
cells (Upper) and decreases production of BDNF (Lower). *, P  0.05 between
ILK siRNA treatment (ILK-A) and nonspecific siRNA controls (NC). (E) Primary
neurons are damaged by 24 h of hypoxia (CON). Conditioned media from
endothelial cells treated with nonspecific siRNA (NC) is neuroprotective. But
when conditioned media is obtained from endothelial cells previously treated
with ILK siRNA (ILK-A), neuroprotection is significantly decreased. *, P  0.05
versus untreated hypoxic neurons; #, P  0.05 between NC and ILK-A condi-
tions. Neither siRNA nor the drug ILK inhibitors were directly cytotoxic.











































trophic factors. How these matrix-trophic pathways operate in
vivo in various brain diseases remains to be elucidated. Finally,
for the sake of experimental clarity, we focused on endothelial
cells. However, in vivo interactions between the vascular system
and the brain parenchyma cannot occur without astrocytes (38).
How would matrix-trophic signals ‘‘go through’’ the glial layer?
What astrocytic mediators might regulate endothelial gene
expression and vice versa? Ultimately, neurovascular signaling
cannot be fully dissected without taking astrocytes and other
glial cells into consideration.
Our findings demonstrate that endothelial cells can secrete
potent neuroprotective factors. We speculate that the cerebral
endothelium might even comprise a ‘‘neuroprotective organ’’
within the brain itself. Fundamentally, this new concept may
force us to revise our current understandings of neuroprotection.
Loss of homeostatic coupling from unhealthy cerebral endothe-
lial cells will lead to dysfunctional neurons. An overwhelming
number of clinical neuroprotection trials have failed, perhaps
because they only focused on saving neurons. Targeting the
cerebral endothelium and salvaging its matrix-trophic signals
may broadly provide new therapeutic opportunities against
stroke, brain injury, and neurodegeneration.
Experimental Procedures
Cell Cultures. Primary mouse brain microvascular endothelial cells (39, 40) were
cultured from 4-week-old male mice, purified with anti-murine CD31 pre-
coated M-450 Dynabeads (Dynal), plated onto type I collagen-coated multi-
well plates (BD Bioscience), and cultured in complete medium consisting of
DMEM/F12, 10% horse serum, 10% FCS (Invitrogen), 0.1 mg/ml endothelial cell
growth supplement (BD Bioscience), 100 g/ml Heparin (Sigma), and 100
units/ml penicillin and streptomycin. Mouse endothelial cells were split at a
ratio of 1:2 and used at passages 2–3. Additionally, we used a human brain
microvascular endothelial cell line with confirmed endothelial characteristics
(41). Cells were maintained in complete medium consisting of RPMI medium
1640 (Invitrogen), 10% FBS, 10% NuSerum (BD Biosciences), 1 mM sodium
pyruvate, nonessential amino acids, MEM vitamins, and 100 units/ml penicillin
and streptomycin. Rat neurons were cultured from embryonic day 17 embry-
onic cortices, and isolated cells were plated onto poly-D-lysine-coated 12-well
plates with medium consisting of NeuroBasal, 2% B27 (Invitrogen), 0.3 mM
L-glutamine, and 100 units/ml penicillin and streptomycin. Medium were half
changed every 3 days, and cells were used at days in vitro 7–9. The human
neuroblastoma cell line SH-SY5Y was obtained from ATCC and cultured in
DMEM/F12 with 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin.
For cocultures, cerebral endothelial cells were plated into 12-mm transwell
inserts (Corning Costar) coated with type I collagen for mouse primary endo-
thelial cells or human plasma fibronectin (HFN; BD Bioscience) for human
endothelial cells, in each complete medium until 70–80% cell density. The day
before coculture and hypoxia, endothelial cells were changed to serum-free
DMEM/F12, and rat cortical neurons were also starved gradually by half
change of medium with mixed medium NeuroBasal/DMEM/F12 (1:1). Right
before hypoxia treatment, the transwells with endothelial cells were placed
above the neuron cells in fresh serum-free DMEM/F12 and stayed together for
hypoxia and after reoxygenation. For conditioned media transfer experi-
ments, cerebral endothelial cells were plated into HFN-coated dishes at 50%
cell density and changed to fresh media after 16-h starvation with mixed
serum-free medium NeuroBasal/RPMI medium 1640 (1:1). This serum-free
media was collected 24 h later and used as E-CM for transfer to rat neurons or
SH-SY5Y when assessing neuroprotection.
Cell Treatment Conditions. Hypoxia was induced with a modular chamber
(Billups-Rothenberg) perfused with 90% N2, 5% H2, and 5% CO2 for 30 min at
37°C. The chamber was then sealed and kept at 37°C for indicated time periods
for hypoxia. At the end of hypoxia exposure, cells were removed from the
chamber and returned to a regular incubator for reoxygenation. Control
cultures were incubated in a regular incubator under normoxic condition for
the corresponding hypoxic duration. Amyloid- peptide (A 1–40) (Bio-
source), preaged at 4°C for 3 days, was added to cells for 24 h as another injury
for rat primary neurons after 3-h starvation. Neuroblastoma SH-SY5Y cells
were also used to look for neuroprotection of E-CM against OGD, oxidative
damage with H2O2, and ER stress. Cells were plated in multiwell plates at 80%
density and switched into serum-free DMEM/F12 for 8 h before exposure to
stimulations. For OGD, cells were exposed to glucose-free DMEM within a
hypoxic chamber for 8 h followed by a return to normoxic condition with fresh
DMEM/F12 or E-CM for 12 h. For oxidative stress, 100 m H2O2 was added for
30 min followed by a change to fresh DMEM/F12 or E-CM for 24 h. For ER stress,
cells were exposed to 100 nM thapsigargin (Sigma) for 24 h in DMEM/F12 or
E-CM. To assess cerebral endothelial responses, cells were plated into HFN-
coated multiwell plates overnight, serum-starved for 8 h, then changed to
fresh RPMI medium 1640 with 0.5% FBS plus A 1–40 or SNP (Sigma). Cell
death was quantified by using standard MTT and lactate dehydrogenase
(LDH) release assays. To examine the role of integrins in our system, we used
8A2 (generous gift from John Harlan, Washington University, St. Louis),
mAb13, and the small molecule ILK inhibitor KP-392, in serum-free media
RPMI medium 1640. Twenty hours postexposure, the media were collected for
measurement. To check the specificities of our 1 integrin antibodies, the
stimulating antibody 8A2 was added to the media after 2-h pretreatment with
the blocking antibody mAb13. No observable cytotoxicity was detected with
these various integrin antibody and ILK inhibitor treatments.
BDNF Procedures and Assays. E-CM were filtered with recombinant human
TrkB-Fc chimera (R&D Systems) to remove BDNF. Briefly, 2.0 g/ml TrkB-Fc was
added to media for 2 h in 4°C with rotation, and equal amounts of normal
human IgG (Zymed) were added as control. Protein A-agarose immunopre-
cipitation reagent was then added for overnight in 4°C with rotation. The
media were centrifuged to discard the agarose pellet, and the filtered super-
natant was used for conditioned media experiments and BDNF measurement.
Recombinant human BDNF (Peprotech) was used for add-back experiments
with the filtered conditioned media transfer protocols. BDNF levels were
measured by using the BDNF Emax ImmunoAssay System (Promega).
siRNA. Cerebral endothelial cells were transfected with 100 nM siRNA ILK-A,
that specifically targets the ILK gene (42), and NC using 4 l of Oligofectamine
(Invitrogen) according to the manufacturer’s instructions. The cells were split
at 48 h posttransfection and plated onto HFN-coated dishes. The serum-free
media with 24 h-exposure after overnight starvation was collected for condi-
tioned media experiment or BDNF measurement. Note that no significant
toxicity was observed for these siRNA treatments overall.
Immunoblotting. Cells were lysed in lysis buffer (Cell Signaling Technology)
and clarified, and protein concentration was determined with the Bradford
assay (Bio-Rad). Total lysates of cells (30 g per lane) were separated in precast
12% Tris-glycine SDS-polyacrylamide gels (Invitrogen), and proteins were
transferred to PVDF membrane (Invitrogen). After blocking with 0.2% I-block
(Tropix), membranes were incubated overnight at 4°C with indicated primary
antibodies, and 1 h at room temperature with horseradish peroxidase-
conjugated secondary antibodies (Amersham). The immune complexes were
visualized by enhanced chemiluminescence (Amersham). All immunoblots
were repeated for at least three independent experiments.
Statistical Analysis. All of experiments were done in duplicate or triplicate,
repeated two to five times independently. Quantitative data were expressed
as mean / SD and analyzed with ANOVA followed by Tukey HSD multiple
comparisons. Differences of P  0.05 were considered significant.
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